1 Department of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Chiayi branch, Taiwan.
2 Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419869491. doi: 10.1177/1534735419869491.
Metformin use reportedly reduces cancer risk and improves survival in lung cancer patients. This study aimed to investigate the effect of metformin use in patients with diabetes mellitus (DM) and lung cancer receiving epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. A nationwide, population-based cohort study was conducted using the Taiwan National Health Insurance Research Database. From January 1, 2004, to December 31, 2012, a total of 373 metformin and 1260 non-metformin lung cancer cohorts with type 2 DM and EGFR-TKI treatment were studied. Metformin use was significantly associated with a reduced risk of death (hazard ratio: 0.73, 95% confidence interval [CI]: 0.62-0.85, < .001), as well as a significantly longer median progression-free survival (9.2 months, 95% CI: 8.6-11.7, vs 6.4 months, 95% CI: 5.9-7.2 months, < .001) and median overall survival (33.4 months, 95% CI: 29.4-40.2, vs 25.4 months, 95% CI: 23.7-27.2 months, < 0.001). In conclusion, metformin may potentially enhance the therapeutic effect and increase survival in type 2 DM patients with lung cancer receiving EGFR-TKI therapy.
据报道，二甲双胍的使用可以降低肺癌患者的癌症风险并改善其生存。本研究旨在调查二甲双胍在接受表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗的糖尿病（DM）合并肺癌患者中的作用。
使用台湾全民健康保险研究数据库进行了一项全国性的基于人群的队列研究。从 2004 年 1 月 1 日至 2012 年 12 月 31 日，共研究了 373 例接受二甲双胍治疗和 1260 例未接受二甲双胍治疗的 2 型 DM 合并 EGFR-TKI 治疗的肺癌队列。二甲双胍的使用与降低死亡风险（风险比：0.73，95%置信区间[CI]：0.62-0.85，<0.001）以及显著延长中位无进展生存期（9.2 个月，95%CI：8.6-11.7，vs 6.4 个月，95%CI：5.9-7.2 个月，<0.001）和中位总生存期（33.4 个月，95%CI：29.4-40.2，vs 25.4 个月，95%CI：23.7-27.2 个月，<0.001）显著相关。
总之，二甲双胍可能会增强接受 EGFR-TKI 治疗的 2 型 DM 合并肺癌患者的治疗效果并提高其生存率。
